• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
tebu-bio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Cell Biology and Signalling

5 multicolour flow cytometry reagents for immunophenotyping

19/08/2016 by Philippe Fixe, PhD No Comments
Dual CD4 CD3 leukocyte staining by FCM Exbio tebu-bio

Multicolour fluorochrome reagents have spurred researchers’ capacity to analyze cell populations and to isolate cell subsets by flow cytometry. In this post, let’s take at look at the advantages of 5 optimized combinations of mixed fluorochromes you should consider for your next immunophenotyping assays by multicolour flow cytometry.

Continue reading
Cell Sourcing - Cell Culture Technologies, Headlines

“Extraordinary” CAR T Cells eliminate cancer after stem cell transplant

07/04/2016 by Jean-François Têtu, PhD No Comments
T Regs primary cells by tebu-bio

Donor-derived lymphocytes attack a patient’s cancer — but may attack the patient as well. Donor chimeric antigen receptor (CAR) T cells, on the other hand, brought remissions without this troubling complication.

CAR T cells continue to make waves: At the latest annual meeting of the American Association for the Advancement of Science, it was announced that CAR T cells, in which T cells from a patient are genetically reprogrammed to target cancer cells, removed all traces of cancer in the bone marrow of 27 out of 29 acute lymphoblastic leukemia patients. Nineteen of 30 individuals with non-Hodgkin lymphoma also responded in the form of partial or complete responses. The cumulative successes found in CAR T cell studies have labeled them “extraordinary.”[1]

Continue reading
Headlines

New drug for Sickle Cell Disease targets Leukocytes

11/06/2015 by Jean-François Têtu, PhD No Comments

Leukocytes adhere to blood vessels as a mechanism to enter tissue where there is inflammation. Inadvertently, they pile up sickle cell red blood cells.

Mutations in the hemoglobin gene can render a person to a lifetime of sickle cell disease (SCD). While otherwise healthy individuals with one allele (gene copy) of the sickle hemoglobin (HbS) gene are carriers, the disease is seen in those with two HbS alleles – one inherited from each carrier parent. A single HbS allele can also cause SCD in a person who inherits other defects in the second hemoglobin allele.

Continue reading
Biomarkers, Cell Sourcing - Cell Culture Technologies, Drug Discovery, Supplying Discovery Tools

PBMCs & drug development

19/03/2015 by Jean-François Têtu, PhD 2 Comments

Use of human samples including peripheral blood mononuclear cells (PBMCs) in drug discovery is critical for increasing the chances of success for a small molecule screen hit. A review based on recent published data!

PBMCs DD 1Several theories try to explain why many drug discovery and development projects have a moderate success rate. Even with the advances made in methods (HTS, HCA, library managment, etc), there are many hurdles for a small molecule on the long road to FDA or EMA approval.

One way that may improve predicted efficacy and toxicity of drug leads is to use human samples, such as blood, early on in drug discovery programs. Peripheral blood mononuclear cells  (PBMCs) can be easily used in a variety of ways during the drug discovery process to gain a better understanding of the effects of a small molecule.

Continue reading
Page 1 of 212»
tebu-bio

LAB SERVICES OUTSOURCING

• Protein production

• Plasmid Preps

• 3D Cell Culture
LEARN MORE

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
  • From RUO to IVD - the acronym guide to reagents' intended use
My Tweets

Top contributors

Dimitri Szymczak, PhD
Dimitri Szymczak, PhD
  • How can you get your mRNA ready in only a few weeks?
  • CleanCap: The new capping standard for self-amplifying mRNA
Frédéric Samazan
Frédéric Samazan
  • Immuno-Oncology: 6 must-haves to boost your projects
  • MagIC Beads – The future of RNA capture kits
Isabelle Nobiron, PhD
Isabelle Nobiron, PhD
  • COVID-19: relevant cell culture models
  • Immunoassay development: reliable sources of quality reagents
Isabelle Topin, PhD
Isabelle Topin, PhD
  • Antibody Purification: Tips and Tricks
  • Monoclonal antibodies – all you need to know about antibody generation
Philippe Fixe, PhD
Philippe Fixe, PhD
  • How to monitor inflammatory cytokines in anti-COVID drug discovery
  • New SARS-CoV/ACE2 inhibitor assays & small molecules for drug discovery

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com